Precision Targeting of the Malignant Clone in Diffuse Large B Cell Lymphoma Using Chimeric Antigen Receptor T Cells Against the Clonotypic IGHV4-34 B Cell Receptor
Ivan Cohen(Hospital of the University of Pennsylvania), Marco Ruella(Parker Institute for Cancer Immunotherapy), Giulia Gabrielli(Hospital of the University of Pennsylvania), Jaryse Harris(Hospital of the University of Pennsylvania), Guido Ghilardi(Hospital of the University of Pennsylvania), Κώστας Σταματόπουλος(Centre for Research and Technology Hellas), Scott A. Jenks(Emory University), Patrizia Porazzi(Hospital of the University of Pennsylvania), Stephen J. Schuster(Hospital of the University of Pennsylvania), Igñacio Sanz(Emory University), Raymone Pajarillo(Hospital of the University of Pennsylvania), Paolo Ghia(Vita-Salute San Raffaele University), Audrey Bochi-Layec(University of Pennsylvania), Ki Hyun Kim(Chonnam National University Hwasun Hospital), Yunlin Zhang(Hospital of the University of Pennsylvania), Ositadimma Ugwuanyi(Hospital of the University of Pennsylvania), Liping Wang(Chinese Center For Disease Control and Prevention), Elisavet Vlachonikola(Aristotle University of Thessaloniki)
Cited by 3
Related Papers
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
GABA-modulating bacteria of the human gut microbiota
|Nature Microbiology|2018|1.1k